Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 1,24(s)-dihydroxyvitamin D2
2. 1,24-dihydroxyvitamin D2
3. 1alpha,24(s)(oh)2d2
4. 1alpha,24(s)-dihydroxyvitamin D2
5. Lr-103
1. Lr-103
2. 156316-85-7
3. 2900i92z36
4. (24s)-1alpha,24-dihydroxyvitamin D2 / (24s)-1alpha,24-dihydroxyergocalciferol
5. (5z,7e,22e)-(1s,3r,24s)-9,10-seco-5,7,10(19),22-ergostatetraene-1,3,24-triol
6. Unii-2900i92z36
7. Lmst03010062
8. 1alpha,24(s)-dihydroxyergocalciferol
9. Schembl3026089
10. Lr 103 [who-dd]
11. Dtxsid801015488
12. Zinc4791507
13. Db06117
14. (1alpha,3beta,5z,7e,22e,24s)-9,10-secoergosta-5,7,10(19),22-tetraene-1,3,24-triol
15. 1.alpha.,24s-dihydroxyvitamin D2
16. 1.alpha.,24(s)-dihydroxyergocalciferol
17. Q27254357
18. (1.alpha.,3.beta.,5z,7e,22e,24s)-9,10-secoergosta-5,7,10(19),22-tetraene-1,3,24-triol
19. 9,10-secoergosta-5,7,10(19),22-tetraene-1,3,24-triol,(1.alpha.,3.beta.,5z,7e,22e)-
| Molecular Weight | 428.6 g/mol |
|---|---|
| Molecular Formula | C28H44O3 |
| XLogP3 | 5.1 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 5 |
| Exact Mass | 428.32904526 g/mol |
| Monoisotopic Mass | 428.32904526 g/mol |
| Topological Polar Surface Area | 60.7 Ų |
| Heavy Atom Count | 31 |
| Formal Charge | 0 |
| Complexity | 760 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 7 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 3 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in parathyroid disorders.
LR-103 is effective in normalizing serum calcium and PTH levels without causing hypercalcemia. Importantly, LR-103 also normalized bone abnormalities consequent to SHPT and active vitamin D deficiency.
ABOUT THIS PAGE
A Lr-103 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lr-103, including repackagers and relabelers. The FDA regulates Lr-103 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lr-103 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Lr-103 supplier is an individual or a company that provides Lr-103 active pharmaceutical ingredient (API) or Lr-103 finished formulations upon request. The Lr-103 suppliers may include Lr-103 API manufacturers, exporters, distributors and traders.
click here to find a list of Lr-103 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Lr-103 DMF (Drug Master File) is a document detailing the whole manufacturing process of Lr-103 active pharmaceutical ingredient (API) in detail. Different forms of Lr-103 DMFs exist exist since differing nations have different regulations, such as Lr-103 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Lr-103 DMF submitted to regulatory agencies in the US is known as a USDMF. Lr-103 USDMF includes data on Lr-103's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Lr-103 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Lr-103 suppliers with USDMF on PharmaCompass.
Lr-103 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Lr-103 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Lr-103 GMP manufacturer or Lr-103 GMP API supplier for your needs.
A Lr-103 CoA (Certificate of Analysis) is a formal document that attests to Lr-103's compliance with Lr-103 specifications and serves as a tool for batch-level quality control.
Lr-103 CoA mostly includes findings from lab analyses of a specific batch. For each Lr-103 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Lr-103 may be tested according to a variety of international standards, such as European Pharmacopoeia (Lr-103 EP), Lr-103 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lr-103 USP).
LOOKING FOR A SUPPLIER?
